SOLARIS Study: For Neovascular "wet" age related Macular Degeneration

Official Title: A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy ofintravitreous administration of fovista™ (anti pdgf-b pegylated aptamer) administered incombination with either avastin® or eylea® compared to avastin® or eylea® monotherapy insubjects with subfoveal neovascular age-related macular degeneration


The purpose of this study is to evaluate Fovista drug administered in combination with Avastin or Eylea for "wet" neovascular macular degeneration.

Eligibility criteria:

- Age 50 and older
- Newly diagnosed, previously untreated neovascular "wet" age related macular degeneration

Contact Information

Will Bloom